|By Business Wire||
|March 21, 2014 07:00 AM EDT||
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Fast Company Co.Exist on March 19.
The article, “Lab-Grown Organs Are Out In The Wild, And More Are Coming Soon,” recounts the Company’s success to date in regenerating tracheas and the technology involved. It additionally notes the Company “sees a booming business in lab-grown organs” and that it is “the only organization to approach the FDA and the EMA about clinical trials to take the technology to market.”
To read the Fast Company Co.Exist article in its entirety, please visit the following link: http://www.fastcoexist.com/3027468/lab-grown-organs-are-out-in-the-wild-and-more-are-coming-soon
The article at the link above is provided for informational purposes only. Harvard Apparatus Regenerative Technology, Inc. is not responsible for the content of the linked article.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreathTM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Aug. 30, 2016 07:00 PM EDT Reads: 912
Aug. 30, 2016 06:15 PM EDT Reads: 329
Aug. 30, 2016 05:45 PM EDT Reads: 3,586
Aug. 30, 2016 05:00 PM EDT Reads: 892
Aug. 30, 2016 04:15 PM EDT Reads: 960
Aug. 30, 2016 03:30 PM EDT Reads: 3,775
Aug. 30, 2016 03:00 PM EDT Reads: 854
Aug. 30, 2016 02:30 PM EDT Reads: 1,041
Aug. 30, 2016 02:30 PM EDT Reads: 954
Aug. 30, 2016 02:00 PM EDT Reads: 3,780
Aug. 30, 2016 01:45 PM EDT Reads: 658
Aug. 30, 2016 01:30 PM EDT Reads: 871
Aug. 30, 2016 01:20 PM EDT Reads: 272
Aug. 30, 2016 01:15 PM EDT Reads: 2,067
Aug. 30, 2016 01:00 PM EDT Reads: 3,236